ASH Guidelines on Sickle Cell Disease: Stem Cell Transplantation Supplement 2: Disclosure Forms of Panelists

Françoise Bernaudin, MD

Javier Bolaños-Meade, MD

Courtney Fitzhugh, MD

Jane Hankins, MD, MS

Julie Kanter, MD

Robert Liem, MD

Joerg Meerpohl, MD

Julie Panepinto, MD, MSPH

Damiano Rondelli, MD

Shalini Shenoy, MD

John Tisdale, MD

John Wagner, MD

Mark Walters, MD

Teonna Woolford

ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☒ No

   ☐ Yes, as described below:

   Add rows as needed for each employment relationship.

Company	*Description*	*End Date*	*For ASH Internal Use*

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

   ☒ No

   ☐ Yes, as described below:

   Add rows as needed for each equity interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Add rows as needed for each patent or royalty interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No

☒ Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each activity.

Company	*Description*	*End Date*	*For ASH Internal Use*
Addmedica	Support for participation in ASH meeting in San Diego Travel, registration	Dec 2016	Ended before appointment.
Novartis	Support for registration and travel to meeting in Strasbourg France March 2016	March 2016	Ended before appointment.

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

☒ No

☐ Yes, as described below:

Add rows as needed for each interest.

Company	*Description*	*End Date*	*For ASH Internal Use*

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No

☒ Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

Company	*Description of Research*	*My Role*	*End Date*	*For ASH Internal Use*
Novartis	Research funding	To provide anonymized data from our site data base	Sept 2014	Ended before appointment.

Company	*Description of Research*	*My Role*	*End Date*	*For ASH Internal Use*

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each organization.

Organization	*Description and role*	*Paid or Unpaid?*	*End Date*	*For ASH Internal Use*

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Stem Cell Transplantation for Sickle Cell Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

   ☐ No

   ☒ Yes

   If yes, please explain: I believe that genoidentical HSCT is the best choice of treatment for a SCA-patient with severity markers such as frequent VOC or ACS or presence of cerebral vasculopathy

   Several publications (see below)

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

   ☐ No

   ☒ Yes

   If yes, what were those views and where were they made?

   We have participated in the international trial reported by Mark Walters in NEJM 1996

   We have reported the French experience in Blood 2007 and in 2 abstracts at ASH meetings

   Blood 2010 and 2013

   We have participated in the European review about SCT for hemoglobinopathies published in "Haematologica" in 2014

A review has been recently invited and submitted to World Journal of Transplantation

Concerning haplo-identical transplantations, we have participated in the abstract presented at the last ASH meeting 2016 and I had been invited to write the "inside Blood" in 2012 concerning the first report by the Baltimore team of haplo-transplants for SCD patients

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

☐ No

☒ Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

Funder	*Description of Research*	*My Role*	*End Date*
French government	DrepaGreffe is a national French multicenter prospective trial comparing chronic transfusion and stem cell transplantation for SCA-children on chronic transfusion for a history of abnormal-TCD	Principal investigator	January 2017

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

   ☐ Don't know

   ☒ No

   ☐ Yes

   If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

   ☐ Don't know

   ☒ No

   ☐ Yes

   If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

   ☐ Don't know

   ☒ No

   ☐ Yes

   If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

   Not applicable

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

☐ No

☒ Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

Organization	*Relevant Policy Position*	*Your Role*
SFGM-TC (Société Française de Greffe de Moelle et de Thérapie Cellulaire)	French society of HSCT	Member Coordinator of the work about HSCT for SCD (1992-2014)
DrepaGreffe association	Information, Education concerning SCT for SCD patients using ex-SCD patients transplanted testimonies	President

Clinical Practice

9. Do you see patients clinically?

☒ No because recently retired

☐ Yes

If yes, what is your primary specialty or subspecialty? Hemato-pediatrics

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

☒ No

☐ Yes

If yes, please explain:

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

    ☒ No

    ☐ Yes

    If yes, please describe:

Part D. New Declarations (ASH Internal Use)

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
Addmedica	Direct payment received for a conference talk given to scientists about HSCT and SCD in November 2017.	1/4/2018	Indirect conflict. Addmedica markets hydroxyurea (Siklos). Although hydroxyurea will not be addressed in this guideline, the company could be indirectly affected by recommendations about transplantation because patients with successful transplants would not be candidates for this drug.
Addmedica	Received a travel and registration grant to attend the ASH 2017 Annual Meeting	1/4/2018	Indirect conflict. Addmedica markets hydroxyurea (Siklos). Although hydroxyurea will not be addressed in this guideline, the company could be indirectly affected by recommendations about transplantation because patients with successful transplants would not be candidates for this drug.
Bluebird Bio	Scheduled to receive direct payment for consulting	1/4/2018	Indirect conflict. Bluebird Bio is developing a gene editing platform for use in SCD patients. Although gene therapy will not be addressed in this guideline, the

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
			company could be indirectly affected by recommendations about transplantation because gene therapy is being developed as an alternative treatment to transplantation.
Addmedica	Received a travel and registration grant to attend the ASH 2018 Annual Meeting	12/10/2018	Indirect conflict as noted above.
Addmedica	Received a travel and registration grant to attend the ASH 2019 Annual Meeting	9/25/2020	Indirect conflict as noted above.
Bluebird Bio	Direct payment for consulting	9/25/2020	Indirect conflict. Bluebird Bio is developing a gene editing platform for use in SCD patients. Although gene therapy will not be addressed in this guideline, the company could be indirectly affected by recommendations about transplantation because gene therapy is being developed as an alternative treatment to transplantation.
Global Blood Therapeutics	Direct payment for advisory board participation at EHA 2019 meeting	9/25/2020	Indirect conflict. GBT markets voxelotor. Although voxelotor will not be addressed in this guideline, the company could be indirectly affected by recommendations about transplantation

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
			because patients with successful transplants would not be candidates for this drug.

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH Guideline Panel on Stem Cell Transplantation for Sickle Cell Disease

Summary of ASH Judgments About Financial Conflicts

Reviewer name and date	*Direct Financial Conflicts?*	*Indirect Financial Conflicts?*	*Management Notes*
Webb 3/2/17 Pai 3/13/17	No	No	
Webb 1/4/18; Kunkle 1/16/18	No	Yes	New disclosures, see Part D: Dr. Bernaudin reports direct payments or other transfers of value from Addmedica, Novartis, and Bluebird Bio. These companies are either marketing or developing disease-modifying therapies for SCD that could be viewed as competitive with transplantation. These indirect conflicts will be managed through disclosure and panel composition. Recusal will not be required. "Other notes" added below.
Lottenberg 1/24/17	No	Yes	
Webb 12/12/18	No	Yes	New disclosure, see Part D: Dr. Bernaudin reports receiving direct payments or other transfers of value from Addmedica. As noted above this is an indirect conflict and will be managed through disclosure and panel composition. Recusal will not be required.
Alexander 11/2/2020	No	Yes	New disclosures. See Part D: Dr. Bernaudin reports receiving direct payments or other transfers of value from Addmedica, GBT and Bluebird Bio. As noted above these are indirect conflicts and will be managed through disclosure and panel composition.

			On 9/25/2020, Dr. Bernaudin confirmed all information in this form.

Summary of Direct Financial Conflicts

Company	*Description*	*Disclosure Date*	*ASH Notes*

Other Notes

Dr. Bernaudin has participated in and published about seminal research on stem cell transplant for SCD. She was the principal investigator for a recently completed trial funded by the French government comparing chronic transfusion and stem cell transplantation for SCA-children on chronic transfusion for a history of abnormal TCD. Dr. Bernaudin is a recently retired pediatric hematologist. She is the president of DrepaGreffe, a nonprofit advocacy organization that promotes information and education about transplantation for SCD. She reports that she believes that “genoidentical HSCT is the best choice of treatment for a SCA-patient with severity markers such as frequent VOC or ACS or presence of cerebral vasculopathy.”

ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☒ No

   ☐ Yes, as described below:

   Add rows as needed for each employment relationship.

Company	*Description*	*End Date*	*For ASH Internal Use*

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

   ☒ No

   ☐ Yes, as described below:

   Add rows as needed for each equity interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Add rows as needed for each patent or royalty interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No

☒ Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each activity.

Company	*Description*	*End Date*	*For ASH Internal Use*
Incyte	DSMB Monitor	12/31/16	Ended before appointment.

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

☒ No

☐ Yes, as described below:

Add rows as needed for each interest.

Company	*Description*	*End Date*	*For ASH Internal Use*

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☒ No

   ☐ Yes, as described below:

   Column 1 Name the company funding or supporting the research.

   Column 2 Briefly describe the research project.

   Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

   Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

   Add rows as needed for each research project.

Company	*Description of Research*	*My Role*	*End Date*	*For ASH Internal Use*

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces,

markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each organization.

Organization	*Description and role*	*Paid or Unpaid?*	*End Date*	*For ASH Internal Use*

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Stem Cell Transplantation for Sickle Cell Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

   ☒ No

   ☐ Yes

   If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

   ☐ No

   ☒ Yes

   If yes, what were those views and where were they made?

   Bloo Rev 2014; 28(6):243-8

   Curr Opin Oncol 2009; 21(2):158-61

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

☒ No

☐ Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

Funder	*Description of Research*	*My Role*	*End Date*

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

☒ Don't know

☐ No

☐ Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

☐ Don't know

☒ No

☐ Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

   ☒ Don't know

   ☐ No

   ☐ Yes

   If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

   I am sure I will be fully backed.

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

   ☒ No

   ☐ Yes, as described below:

   Column 1 Name the organization.

   Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

   Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

   Add rows as needed for each organization.

Organization	*Relevant Policy Position*	*Your Role*

Clinical Practice

9. Do you see patients clinically?

☐ No

☒ Yes

If yes, what is your primary specialty or subspecialty?

Oncology/Haematology- Bone marrow transplantation

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

☐ No

☒ Yes

If yes, please explain:

I am involved on recommending BMT to patients with sickle cell disease

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

☒ No

☐ Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
Incyte	Dr. Bolaños-Meade expects to receive direct payment for his role on a Data Safety Monitoring Board (DSMB). The DSMB is for safety (not efficacy) monitoring of a phase 3 study (placebo controlled) for graft-versus-host disease therapy.	1/2/19	Indirect conflict. Incyte is investigating a variety of targeted therapies for cancer and other conditions. Two therapies in development are for graft-vs-host disease; a post-transplant complication relevant but not specific to SCD patients. These products are not yet to market and will not be addressed in the guidelines; however, the company could be indirectly affected by recommendations on transplant since patients with successful transplants would likely not need such therapies.

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH Guideline Panel on Stem Cell Transplantation for Sickle Cell Disease

Summary of ASH Judgments About Financial Conflicts

Reviewer name and date	*Direct Financial Conflicts?*	*Indirect Financial Conflicts?*	*Management Notes*
Webb 3/9/17; Pai 3/13/17; Kunkle 2/20/18	No	No	
Webb 1/15/19	No	No	New disclosures. See part D. above. Dr. Bolaños-Meade reports future direct payment Incyte. The company could be indirectly affected by this guideline as it is developing therapies for graft-vs-host disease. These indirect conflicts will be managed through disclosure and panel composition. Recusal will not be required.
Alexander 10/27/2020	No	No	On 9/11/2020, Dr. Bolaños-Meade confirmed all information in this form.

Summary of Direct Financial Conflicts

Company	*Description*	*Disclosure Date*	*ASH Notes*

Other Notes

Dr. Bolaños-Meade is an oncologist/hematologist who specializes in bone marrow transplantation. In his clinical practice, he is involved in recommending BMT to patients with sickle cell disease. He has previously published review articles about the use of BMT for patients with SCD.

ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Add rows as needed for each employment relationship.

Company	*Description*	*End Date*	*For ASH Internal Use*

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

☒ No

☐ Yes, as described below:

Add rows as needed for each equity interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Add rows as needed for each patent or royalty interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each activity.

Company	*Description*	*End Date*	*For ASH Internal Use*

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

☒ No

☐ Yes, as described below:

Add rows as needed for each interest.

Company	*Description*	*End Date*	*For ASH Internal Use*

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☒ No

   ☐ Yes, as described below:

   Column 1 Name the company funding or supporting the research.

   Column 2 Briefly describe the research project.

   Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

   Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

   Add rows as needed for each research project.

Company	*Description of Research*	*My Role*	*End Date*	*For ASH Internal Use*

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces,

markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each organization.

Organization	*Description and role*	*Paid or Unpaid?*	*End Date*	*For ASH Internal Use*

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Stem Cell Transplantation for Sickle Cell Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

   ☐ No

   ☒ Yes

   If yes, please explain: I believe that there should not be one conditioning regimen for all patients with sickle cell disease but the regimen should be tailored to the group being studied. Also, there should be appropriate stopping rules to prevent excessive complications such as graft rejection and graft-versus-host disease. Lastly, the eligibility criteria should be tailored so that the benefits to the population being studied outweigh the risks.

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

   ☐ No

   ☒ Yes

   If yes, what were those views and where were they made? The above views were shared at my ASH Educational Spotlight Session in 2016. Also similar views have been published in review articles and commentaries.

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

☐ No

☒ Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

Funder	*Description of Research*	*My Role*	*End Date*
NIH intramural	Haploidentical transplant for SCD	Principal investigator	ongoing

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

☐ Don't know

☒ No

☐ Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

☐ Don't know

☒ No

☐ Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

☐ Don't know

☒ No

☐ Yes

If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

My views are similar to other investigators that I work with so my mentor would be supportive. I would also be clear that any views expressed are my own and not necessarily that of the NIH.

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

☒ No

☐ Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

Organization	*Relevant Policy Position*	*Your Role*

Clinical Practice

9. Do you see patients clinically?

☐ No

☒ Yes

If yes, what is your primary specialty or subspecialty?

Adult Hematology

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

☐ No

☒ Yes

If yes, please explain:

My primary research involves nonmyeloablative haploidentical peripheral blood stem cell transplantation for patients with sickle cell disease

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

☒ No

☐ Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH Guideline Panel on Stem Cell Transplantation for Sickle Cell Disease

Summary of ASH Judgments About Financial Conflicts

Reviewer name and date	*Direct Financial Conflicts?*	*Indirect Financial Conflicts?*	*Management Notes*
Webb 2/24/17; Pai 3/13/17; Kunkle 2/20/18	No	No	
Webb 12/12/18	No	No	
Alexander 10/27/2020	No	No	On 9/11/2020, Dr. Fitzhugh confirmed all information in this form.

Summary of Direct Financial Conflicts

Company	*Description*	*Disclosure Date*	*ASH Notes*

Other Notes

Dr. Fitzhugh is a hematologist and researcher at the National Institutes of Health. Her research is focused on nonmyeloablative haploidentical peripheral blood stem cell transplantation for patients with sickle cell disease. She is the principal investigator on NIH research related to haploidentical transplant for SCD. She has given talks and published review articles and commentaries on topics relevant to these guidelines, including tailored conditioning regimens, stopping rules to prevent complications such as graft rejection and graft-versus-host disease, and eligibility criteria for transplant.

ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☒ No

   ☐ Yes, as described below:

   Add rows as needed for each employment relationship.

Company	*Description*	*End Date*	*For ASH Internal Use*

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

   ☒ No

   ☐ Yes, as described below:

   Add rows as needed for each equity interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Add rows as needed for each patent or royalty interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each activity.

Company	*Description*	*End Date*	*For ASH Internal Use*

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

☒ No

☐ Yes, as described below:

Add rows as needed for each interest.

Company	*Description*	*End Date*	*For ASH Internal Use*

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☐ No

   ☒ Yes, as described below:

   Column 1 Name the company funding or supporting the research.

   Column 2 Briefly describe the research project.

   Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

   Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

   Add rows as needed for each research project.

Company	*Description of Research*	*My Role*	*End Date*	*For ASH Internal Use*

Novartis	New Exjade formulation	PI	2018	Indirect conflict. This research is not related to SCD. However, Novartis could be indirectly affected by this guideline: Novartis is partnering with Intellia Therapeutics to develop a gene editing platform for treatment of SCD. Novartis also markets deferasirox and deferoxamine for iron overload and is developing crizanlizumab to prevent vaso-occlusive crisis. Although neither gene therapy nor crizanlizumab will be addressed in this guideline, the company could be indirectly affected by recommendations about transplantation because gene therapy is being developed as an alternative treatment to transplantation and because patients with successful transplants would not be candidates for crizanlizumab. Usage of iron overload products could be indirectly affected by recommendations about transplant because in SCD, the major cause of Iron overload is red blood cell transfusion – transplantation can influence the need for transfusion (pre-transplant and dependent on the outcome of transplant) as well as use of iron chelator therapy.

Company	*Description of Research*	*My Role*	*End Date*	*For ASH Internal Use*
				transplantation.
Global Blood Therapeutics	Phase III GBT440	PI	2018	Indirect conflict. Global Blood Therapeutics is developing GBT 440, a disease-modifying therapy for SCD. Although GBT 440 will not be addressed in this guideline, the company could be indirectly affected by recommendations about transplant because patients with successful transplants would not be candidates for this drug.

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each organization.

Organization	*Description and role*	*Paid or Unpaid?*	*End Date*	*For ASH Internal Use*

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

ASH Guideline Panel on Stem Cell Transplantation for Sickle Cell Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

   ☒ No

   ☐ Yes

   If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

   ☐ No

   ☒ Yes

   If yes, what were those views and where were they made?

   Book chapters: Winthrobe's hematology textbook, and sickle cell anemia from science to clinical practice (Springer).

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

   ☒ No

☐ Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

Funder	*Description of Research*	*My Role*	*End Date*

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

☐ Don't know

☒ No

☐ Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

☐ Don't know

☒ No

☐ Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

   ☐ Don't know

   ☒ No

   ☐ Yes

   If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

   St. Jude and my chair would support my work as long as it has strong scientific relevance and rationale.

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

   ☒ No

   ☐ Yes, as described below:

   Column 1 Name the organization.

   Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

   Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

   Add rows as needed for each organization.

Organization	*Relevant Policy Position*	*Your Role*

Clinical Practice

9. Do you see patients clinically?

☐ No

☒ Yes

If yes, what is your primary specialty or subspecialty?

Pediatric and adult sickle cell disease.

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

☐ No

☒ Yes

If yes, please explain:

Currently I discuss bone marrow transplant with my patients as a therapy option.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

☒ No

☐ Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
Bluebird Bio	Direct payment for consulting on phase III gene therapy. Role end December 2018.	1/17/2018	Indirect conflict. Bluebird Bio is developing a gene editing platform for use in SCD patients. Although gene therapy will not be addressed in this guideline, the company could be indirectly affected by recommendations about transplantation because gene therapy is being developed as an alternative treatment to transplantation.
N/A	Direct payment for consulting role with the National Committee for Quality Assurance(NCQA). NCQA analyzed the patterns of opioid consumption in Medicare patients across the country. Dr. Hankins helped them interpret the data for pain and opioid utilization. Role ended August 2018.	12/27/18	Not a conflict. NCQA is a nonprofit organization.
MJ Lifesciences	Direct payment for presenting at education session	9/11/2020	

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
Vindico Medical Education	Direct payment for presenting at education session during ASH annual meeting	9/11/2020	Not a conflict. Vindico Medical Education is a ACCME accredited medical education company.
NHLBI	mHealth study to increase hydroxyurea adherence. Dr. Hankins is the PI.	9/11/2020	Not a conflict. NHLBI is a U.S. government agency.

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH Guideline Panel on Stem Cell Transplantation for Sickle Cell Disease

Summary of ASH Judgments About Financial Conflicts

Reviewer name and date	*Direct Financial Conflicts?*	*Indirect Financial Conflicts?*	*Management Notes*
Webb 3/3/17; Pai 3/13/17; Webb 12/19/17; Alexander 1/10/18; Kunkle 1/16/18	No	Yes	Dr. Hankins is receiving direct payment from Bluebird Bio. She also has a leadership role on research projects funded by Novartis and Global Blood Therapeutics. All three companies are developing disease-modifying therapies for SCD that could be viewed as competitive with transplantation. Novartis also markets iron overload products, which might be indirectly affected by recommendations about transplantation. Funding for these research projects goes to Dr. Hankins' institution, not to her directly. These indirect conflicts will be managed through disclosure and panel composition. Recusal will not be required.
Lottenberg 1/23/17	No	Yes	See my comment on Novartis iron chelator trial
1/13/19	No	Yes	New disclosure. See Part D. above. Recusal not required.
Alexander 9/28/2020	No	Yes	New disclosures. See Part D. On 9/11/2020, Dr. Hankins confirmed all information in this form.

Summary of Direct Financial Conflicts

Company	*Description*	*Disclosure Date*	*ASH Notes*

Other Notes

Dr. Hankins reports previously published opinions (book chapters) about transplantation. As a clinical specialist in pediatric and adult SCD, she also reports that she discusses transplant with her patients as a therapy option.

ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Add rows as needed for each employment relationship.

Company	*Description*	*End Date*	*For ASH Internal Use*

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

☒ No

☐ Yes, as described below:

Add rows as needed for each equity interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☒ No

   ☐ Yes, as described below:

   Add rows as needed for each patent or royalty interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☐ No

   ☒ Yes, as described below:

   Column 1 Name the company.

   Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each activity.

Company	*Description*	*End Date*	*For ASH Internal Use*
Astrazeneca	Steering Committee	July 2017	Indirect conflict. AstraZeneca markets ticagrelor for treatment of blockages of blood flow to the heart. Ticagrelor is being clinically trialed in SCD patients to reduce pain. Although the drug will not be addressed in this guideline, the company could be indirectly affected by recommendations on transplantation because patients with successful transplants would not be candidates for this drug.
Eli Lily	Steering Committee	September 2016	Ended before appointment.
Imara	Advisory Board	September 2016	Ended before appointment.
Novartis	Advisory Board	Ongoing	Indirect conflict. Novartis is partnering with Intellia Therapeutics to develop a gene editing platform for treatment of SCD. Novartis also markets deferasirox and deferoxamine for iron overload and is developing crizanlizumab to prevent vaso-occlusive crisis. Although neither

Company	*Description*	*End Date*	*For ASH Internal Use*
			gene therapy nor crizanlizumab will be addressed in this guideline, the company could be indirectly affected by recommendations about transplantation because gene therapy is being developed as an alternative treatment to transplantation and because patients with successful transplants would not be candidates for crizanlizumab. Usage of iron overload products could be indirectly affected by recommendations about transplant because in SCD, the major cause of Iron overload is red blood cell transfusion – transplantation can influence the need for transfusion (pre-transplant and dependent on the outcome of transplant) as well as use of iron chelator therapy.
Pfizer	Grant review committee	November 2016	Ended before appointment.

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

☒ No

☐ Yes, as described below:

Add rows as needed for each interest.

Company	*Description*	*End Date*	*For ASH Internal Use*

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No

☒ Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

Company	*Description of Research*	*My Role*	*End Date*	*For ASH Internal Use*
Eli Lilly	Phase III research on SCD drug development	Site PI	9.2016	Ended before appointment.
Astrazeneca	Phase I/II research on SCD drug development	Site PI	2.17.17	Ended before appointment.
Bluebird Bio	Phase I research on SCD drug development	Site PI	Ongoing	Indirect conflict. Bluebird Bio is developing a gene editing platform for use in SCD patients. Although gene therapy will not be addressed in this guideline, the company could be indirectly affected by recommendations

Company	*Description of Research*	*My Role*	*End Date*	*For ASH Internal Use*
				about transplantation because gene therapy is being developed as an alternative treatment to transplantation.
Prolong Pharmaceuticals	Phase I research on SCD drug development	Site PI	Ongoing	Indirect conflict. Prolong Pharmaceuticals is developing PEGylated carboxyhemoglobin bovine (Sanguinate) for treating multiple comorbidities of SCD including vaso-occlusive crisis. Although this drug will not be addressed in this guideline, the company could be indirectly affected by recommendations about transplant because patients with successful transplants would not be candidates for this drug.
Pfizer	Phase III research on SCD drug development	Site PI	Ongoing	Indirect conflict. Pfizer markets opioids, which are used to treat pain, and is developing rivipansel for treatment of vaso-occlusive crisis and PF-04447943 for SCD. Although none of these drugs will not be specifically addressed in this guideline, the company could be indirectly affected by

Company	*Description of Research*	*My Role*	*End Date*	*For ASH Internal Use*
				recommendations about transplantation because patients with successful transplants would not be candidates for these drugs.
Mast Therapeutics	Phase III research on SCD drug development	Site PI	11.2016	Ended before appointment.
Apopharma	Phase III research on SCD drug development	Site PI	Ongoing	Indirect conflict. Apopharma markets deferiprone and deferoxamine for iron overload. Although deferiprone and deferoxamine will not be addressed in this guideline, usage of iron overload products could be indirectly affected by recommendations about transplant because in SCD, the major cause of Iron overload is red blood cell transfusion – transplantation can influence the need for transfusion (pre-transplant and dependent on the outcome of transplant) as well as use of iron chelator therapy.
Novartis	Phase III research on SCD drug development	Co-I	Ongoing	Indirect conflict. Novartis is partnering with Intellia Therapeutics to develop a gene editing platform for treatment of SCD. Novartis also markets deferasirox and deferoxamine for iron overload and is developing crizanlizumab to prevent vaso-occlusive crisis. Although neither

Company	*Description of Research*	*My Role*	*End Date*	*For ASH Internal Use*
				gene therapy nor crizanlizumab will be addressed in this guideline, the company could be indirectly affected by recommendations about transplantation because gene therapy is being developed as an alternative treatment to transplantation and because patients with successful transplants would not be candidates for crizanlizumab. Usage of iron overload products could be indirectly affected by recommendations about transplant because in SCD, the major cause of Iron overload is red blood cell transfusion – transplantation can influence the need for transfusion (pre-transplant and dependent on the outcome of transplant) as well as use of iron chelator therapy.

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☐ No

   ☒ Yes, as described below:

   Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each organization.

Organization	*Description and role*	*Paid or Unpaid?*	*End Date*	*For ASH Internal Use*
Pfizer	Council For Change, member	Paid	January 2017	Ended before appointment.

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Stem Cell Transplantation for Sickle Cell Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

   ☐ No

   ☒ Yes

   If yes, please explain: I have strongly held beliefs based on current data on the utility and appropriateness of haploidentical transplant for sickle cell disease.

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

   ☒ No

   ☐ Yes

   If yes, what were those views and where were they made?

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

☐ No

☒ Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

Funder	*Description of Research*	*My Role*	*End Date*
NHLBI	Sickle cell disease implementation center (not related)	PI	Ongoing

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

☐ Don't know

☒ No

☐ Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

☐ Don't know

☒ No

☐ Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

☐ Don't know

☒ No

☐ Yes

If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

My institution would be proud to have me on this panel and support my role in the decisions.

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

☒ No

☐ Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

Organization	*Relevant Policy Position*	*Your Role*

Clinical Practice

9. Do you see patients clinically?

☐ No

☒ Yes

If yes, what is your primary specialty or subspecialty?

Hematology/Sickle Cell Disease

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

☐ No

☒ Yes

If yes, please explain:

I routinely discuss treatment options (including stem cell transplant) for patients living with sickle cell disease.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

☒ No

☐ Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
Imara	Dr. Kanter reported receiving direct payment for an Advisory Board role for IMR687.	12/15/18	Indirect conflict. Imara is developing a developing a disease-modifying therapy, IMR-687 (a selective phosphodiesterase-9 inhibitor) for the reduction of red blood cell sickling in SCD. This product is not yet to market and will not be addressed in these guidelines. However, the company could be indirectly affected by recommendations on transplant because patients with successful transplants would not need an anti-sickling therapy.
Novartis	Dr. Kanter reported receiving direct payment for a Steering Committee role for Crizanlizumab.	12/15/18	Indirect conflict as noted above.
Global Blood Therapeutics	Dr. Kanter reported receiving direct payment for an Advisory Board role for GBT 440.	12/15/18	Indirect conflict. Global Blood Therapeutics is developing GBT 440, a disease-modifying therapy for SCD. This product is not yet to market and will not be addressed in this guideline. However, the company could be indirectly affected by recommendations

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
			about transplant because patients with successful transplants would not be candidates for this drug.
Ironwood	Dr. Kanter reported receiving direct payment for an Advisory Board role for IW-1701	12/15/18	Indirect conflict. Ironwood Pharmaceuticals is developing IW-1701, a therapy to increase the bioavailability of nitric oxide in the blood with the aim of decreasing complications of SCD. The product is not yet to market and will not be addressed in this guideline. However, the company could be indirectly affected by recommendations on transplant because patients with successful transplants would not be candidates for this drug.
AstraZeneca	Dr. Kanter reported she is now Co-Investigator of HESTIA 3.	12/15/18	Indirect conflict. AstraZeneca is investigating the use of their Brilinta product for the prevention of vaso-occlusive crises in pediatric patients with sickle cell disease. The product will not be addressed in these guidelines; however, the company could be indirectly affected because patients with successful transplants would have less vaso-occlusive crises. All

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
			funding goes to her institution.
AstraZeneca	Dr. Kanter reported receiving direct payment for a Steering Committee role.	12/27/18	Indirect conflict as noted above.
Prolong Pharmaceuticals	Dr. Kanter reported that her Phase 1 research on SCD drug development where she was previously the Site PI, ended in 12/2017.	12/15/18	Indirect conflict as noted above.
ApoPharma	Dr. Kanter reported that her Phase III research on SCD drug development where she was the Site PI will end 01/2019.	12/15/18	Indirect conflict as noted above.
Editas	Dr. Kanter reported receiving direct payment for serving on a gene editing Advisory Board.	12/27/18	Indirect conflict. Editas is in the preclinical phase of using gene editing for the treatment of SCD. Although gene therapy will not be addressed in this guideline, the company could be indirectly affected by recommendations about transplantation because gene therapy is being developed as an alternative treatment to transplantation.
Modus	Dr. Kanter reported receiving direct payment for an Advisory Board role for sevuparin.	12/27/18	Indirect conflict. Modus Therapeutics is developing sevuparin, an anti-adhesion agent with the potential to reduce vaso-occlusion and resulting painful

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
			crises in patients with SCD. This product is not yet to market and will not be addressed in this guideline; however, the company could be indirectly affected by recommendations on transplant since SCD patients undergoing successful transplants would not be candidates for this product.
n/a	PI for National Heart Lung and Blood Institute (NHLBI) RO1 on TCD implementation	12/15/18	NHLBI is a federal agency.
n/a	SCD Advisory Committee for National Heart Lung and Blood Institute (NHLBI)	12/15/18	NHLBI is a federal agency.
n/a	PI Health Resources and Services Administration (HRSA) sickle cell treatment project.	12/15/18	HRSA is a federal agency.
Novartis	Dr. Kanter reported direct payment for consulting and ad board participation.	9/13/20	Indirect conflict as noted above.
Bluebird Bio	Dr. Kanter reported direct payments for consulting.	9/13/20	Bluebird Bio is developing a gene editing platform for use in SCD patients. Although gene therapy will not be addressed in this guideline, the company could be indirectly affected by

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
			recommendations about transplantation because gene therapy is being developed as an alternative treatment to transplantation.
Guidepoint Global	Dr. Kanter reports being an employee of Guidepoint Global.	9/13/20	Not a conflict. Guidepoint Global is a consulting firm that connects advisors/experts, such as Dr. Kanter, with companies in various industries, including healthcare. Guidepoint Global does not market any products used in the diagnosis or treatment of SCD.
Sanofi	Dr. Kanter reports direct payment for advisory board participation	9/13/2020	Indirect conflict. Sanofi is developing a gene therapies for treatment of SCD. Although gene therapy will not be addressed in this guideline, the company could be indirectly affected by recommendations about transplantation because gene therapy is being developed as an alternative treatment to transplantation.
AstraZeneca	Dr. Kanter reports receiving direct payments for advisory board participation.	9/13/2020	Indirect conflict as noted above.

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
NovoNordisk	Data safety and monitoring board participation.	9/13/2020	Indirect conflict. NovoNordisk is developing EPI01 for treatment of sickle cell disease. Although this guideline will not address treatments other than transplantation, the company could be indirectly affected by recommendations about transplantation because gene therapy is being developed as an alternative treatment to transplantation.
Beam Therapeutics	Dr. Kanter reports direct payment for consulting	9/13/2020	Beam Therapeutics is developing a gene editing platform for use in SCD patients. Although gene therapy will not be addressed in this guideline, the company could be indirectly affected by recommendations about transplantation because gene therapy is being developed as an alternative treatment to transplantation.
Agios	Direct payment for an advisory board.	9/13/2020	Agios is not an affected company.

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH Guideline Panel on Stem Cell Transplantation for Sickle Cell Disease

Summary of ASH Judgments About Financial Conflicts

Reviewer name and date	*Direct Financial Conflicts?*	*Indirect Financial Conflicts?*	*Management Notes*
Webb 3/9/17 Pai 3/13/17; Webb 12/19/17; Alexander 1/10/18; Kunkle 1/16/18	No	Yes	Dr. Kanter reports direct payments from AstraZeneca and Novartis. She is also a site PI for research funded by Bluebird Bio, Prolong Pharmaceuticals, Pfizer, and Apopharma. These companies are developing disease-modifying therapies for SCD that could be viewed as competitive with transplantation (Novartis, Bluebird Bio), or they are developing or marketing products that could be indirectly affected by recommendations about transplantation (AstraZeneca, Novartis, Prolong Pharmaceuticals, Pfizer, Apopharma). Funding for the research projects goes to Dr. Kanter's institution, not to her directly. These indirect conflicts will be managed through disclosure and panel composition. Recusal will not be required.
Lottenberg 1/24/18			Please see my comments on requests for clarification and additional information
Webb 12/15/18	No	Yes	New disclosures. See Part D. above. Dr. Kanter reports direct payments from Imara, Global Blood Therapeutics, Novartis, Ironwood AstraZeneca, Editas, and Modus. She is also a Co-Investigator for AstraZeneca. These companies are developing or marketing disease modifying therapies that could be indirectly affected these guidelines.

			Funding for the research project goes to Dr. Kanter's institution, not to her directly. These indirect conflicts will be managed through disclosure and panel composition. Recusal will not be required. Added "Other Notes" below.
Alexander 9/28/2020	No	Yes	New disclosures. See Part D. On 9/13/2020, Dr. Kanter confirmed all information in this form.

Summary of Direct Financial Conflicts

Company	*Description*	*Disclosure Date*	*ASH Notes*

Other Notes

Dr. Kanter is a specialist in adult SCD who reports routinely discussing treatment options (including stem cell transplant) for patients living with SCD. Dr. Kanter is the Principal Investigator on an RO1 grant on TCD implementation funded by the National Heart Lung and Blood Institute (NHLBI); and serves on an SCD Advisory Committee for NHLBI. She is also the Principal Investigator on a sickle cell treatment project funded by the Health Resources and Services Administration (HRSA).

ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☒ No

   ☐ Yes, as described below:

   Add rows as needed for each employment relationship.

Company	*Description*	*End Date*	*For ASH Internal Use*

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

   ☒ No

   ☐ Yes, as described below:

   Add rows as needed for each equity interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Add rows as needed for each patent or royalty interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No

☒ Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each activity.

Company	*Description*	*End Date*	*For ASH Internal Use*
Fresenius – Kabi	Honorarium for participating on DSMB for study	May 2016	Not a conflict. Fresnius Kabi markets transfusion products. However, this paid activity ended before Dr. Liem's appointment to the guideline panel.
Global Blood Therapeutics	Honorarium for consulting on exercise studies for clinical trial	April 2016	Not a conflict. Global Blood Therapeutics is developing GBT 440, a potentially disease-modifying therapy for SCD. However, this paid activity ended before appointment.

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

☒ No

☐ Yes, as described below:

Add rows as needed for each interest.

Company	*Description*	*End Date*	*For ASH Internal Use*

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☐ No

   ☒ Yes, as described below:

   Column 1 Name the company funding or supporting the research.

   Column 2 Briefly describe the research project.

   Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

   Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

   Add rows as needed for each research project.

Company	*Description of Research*	*My Role*	*End Date*	*For ASH Internal Use*
Global Blood Therapeutics	Phase 2a, Open-Label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Exploratory Treatment Effect of GBT440 in Adolescents with Sickle Cell Disease	Site-investigator	Ongoing	Indirect conflict. Global Blood Therapeutics is developing GBT 440, a potentially disease-modifying therapy for SCD. This product is not yet to market, and it will not be addressed specifically by these guidelines. However, the company could be indirectly affected by recommendations about the management of renal and pulmonary complications in that such recommendations could implicitly or explicitly identify a need for a disease-modifying therapy that might prevent the complications. Dr. Liem does not have a leadership role in this research.

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each organization.

Organization	*Description and role*	*Paid or Unpaid?*	*End Date*	*For ASH Internal Use*

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

ASH Guideline Panel on Sickle Cell Disease-Related Cardiopulmonary and Kidney Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

   ☒ No

   ☐ Yes

   If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

   ☐ No

   ☒ Yes

   If yes, what were those views and where were they made?

   The following are literature-supported review articles. However, they do not contain any personal opinions:

   Brandow AM and **Liem RI**. Sickle cell disease in the emergency department: atypical complications and management. Clin Pediatr Emerg Med, 2011; 12:202-12

   Chou S, **Liem RI**, Thompson AA. Challenges of alloimmunization in patients with hemoglobinopathies. Br J Haematol, 2012; 159:394-404

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

☐ No

☒ Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

Funder	*Description of Research*	*My Role*	*End Date*
NHLBI/NIH	K23 research project, entitled "The Physiologic Assessment of Exercise Capacity in Pediatric Sickle Cell Anemia"	Overall principal investigator	Grant ends 7/31/16
Stanley Manne Children's Research Institute Internal Grant Award	Investigator-initiated study, entitled "Autonomic Nervous System Dysfunction and Its Relationship to Acute Vaso-Occlusive Pain episodes in Children with Sickle Cell Anemia: A Feasibility Study"	Overall principal investigator	Grant ends 9/31/16
Division of Hematology, Oncology and SCT Seed Grant	Investigator-initiated study, entitled "Flow-Mediated Dilatation and Arterial Health in Children and Young Adults with Sickle Cell Anemia	Overall principal investigator	12/30/14

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

   ☐ Don't know

   ☒ No

   ☐ Yes

   If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

   ☐ Don't know

   ☒ No

   ☐ Yes

   If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

   ☐ Don't know

   ☒ No

   ☐ Yes

   If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

   The support I receive would simply reflect their approval of my contribution to the field of hematology/sickle cell disease in helping to develop much needed evidence-based guidelines for management of this disease.

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

☒ No

☐ Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

Organization	*Relevant Policy Position*	*Your Role*

Clinical Practice

9. Do you see patients clinically?

☐ No

☒ Yes

If yes, what is your primary specialty or subspecialty?

Pediatric hematology. I am the Director of the Comprehensive Sickle Cell Program at my institution.

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

☐ No

☒ Yes

If yes, please explain:

These proposed guidelines relate directly to management of sickle cell disease. For this reason, many of the our current treatment and diagnostic strategies will be directly addressed by these guidelines.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

☒ No

☐ Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH Guideline Panel on Sickle Cell Disease-Related Cardiopulmonary and Kidney Disease

Summary of ASH Judgments About Financial Conflicts

Reviewer name and date	*Direct Financial Conflicts?*	*Indirect Financial Conflicts?*	*Management Notes*
Webb 8/31/16; Kunkle 9/14/16; Kunkle 1/21/18; Panepinto 1/22/18	No	Yes	Dr. Liem is involved in a research study funded Global Blood Therapeutics. This company is investigating a potentially disease-modifying therapy for SCD and therefore could be indirectly affected by these guidelines. Dr. Liem does not have a leadership role on the study, and all funding goes to his institution. This indirect conflict will be managed by disclosure and panel composition. Dr. Liem is co-chairing the guideline panel with a methodologist who does not have direct or indirect financial conflicts with affected companies, and the majority of the panel does not have the same or similar conflict. Recusal will not be required.
Webb 4/18/19 Panepinto 6/9/2019	No	Yes	Other notes added below. On June 20, 2019 Dr. Liem confirmed all information in this form.

Summary of Direct Financial Conflicts

Company	*Description*	*Disclosure Date*	*ASH Notes*

Other Notes

Dr. Liem's specialty is pediatric hematology, and as the director of a comprehensive SCD program, he sees and treats patients with SCD including for cardiopulmonary and renal complications. He has served as the principal investigator on research studies relevant to this guideline topic that were funded by nonprofit organizations and government agencies, including the physiologic assessment of exercise capacity in pediatric sickle cell anemia, the relationship of autonomic nervous system dysfunction to acute vaso-occlusive pain episodes in pediatric sickle cell anemia, and flow-mediated dilation and arterial health in children and young adults with sickle cell anemia. He has published review articles about managing atypical complications of SCD in the emergency department and about challenges of alloimmunization in patients with hemoglobinopathies. Dr. Liem is now overall principal investigator for a National Heart, Lung, and Blood Institute /National Institutes of Health R01 project, entitled "The Pro-Inflammatory Effects of Acute Exercise in Children with Sickle Cell Anemia."

ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☐ x No

   ☐ Yes, as described below:

   Add rows as needed for each employment relationship.

Company	*Description*	*End Date*	*For ASH Internal Use*

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

   ☐ x No

   ☐ Yes, as described below:

   Add rows as needed for each equity interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ x No

☐ Yes, as described below:

Add rows as needed for each patent or royalty interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ x No

☐ Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each activity.

Company	*Description*	*End Date*	*For ASH Internal Use*

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

☐ x No

☐ Yes, as described below:

Add rows as needed for each interest.

Company	*Description*	*End Date*	*For ASH Internal Use*

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ x No

☐ Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

Company	*Description of Research*	*My Role*	*End Date*	*For ASH Internal Use*

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces,

markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ x No

☐ Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each organization.

Organization	*Description and role*	*Paid or Unpaid?*	*End Date*	*For ASH Internal Use*

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ x No

☐ Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

ASH Guideline Panel on Sickle Cell Disease-Related Stem Cell Transplantation

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

   ☐ x No

   ☐ Yes

   If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

   ☐ x No

   ☐ Yes

   If yes, what were those views and where were they made?

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

☐ No

☐ x Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

Funder	*Description of Research*	*My Role*	*End Date*
European Commission	Project on Guideline Development in Rare Diseases	Co-Investigator; Development of Pilot Guideline using GRADE about transfusions and hydroxyurea therapy in people with SCD	31.12.2016

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

☐ Don't know

☐ x No

☐ Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

☐ Don't know

☐ x No

☐ Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

☐ x Don't know

☐ No

☐ Yes

If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

Don't know.

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

☐ x No

☐ Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

Organization	*Relevant Policy Position*	*Your Role*

Organization	*Relevant Policy Position*	*Your Role*

Clinical Practice

9. Do you see patients clinically?

☐ x No

☐ Yes

If yes, what is your primary specialty or subspecialty?

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

☐ x No

☐ Yes

If yes, please explain:

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

☐ x No

☐ Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH Guideline Panel on Sickle Cell Disease-Related Stem Cell Transplantation

Summary of ASH Judgments About Financial Conflicts

Reviewer name and date	*Direct Financial Conflicts?*	*Indirect Financial Conflicts?*	*Management Notes*
Webb 3/7/17; Pai 3/13/17; Kunkle 2/20/18	No	No	
Alexander 10/27/2020	No	No	On 9/15/2020, Dr. Meerpohl confirmed all information in this form.

Summary of Direct Financial Conflicts

Company	*Description*	*Disclosure Date*	*ASH Notes*

Other Notes

Dr. Meerpohl is a pediatric hematologist/oncologist but does not see patients clinically. He was a co-investigator on a project funded by the European Commission to develop a pilot guideline using GRADE about transfusions and hydroxyurea therapy in people with SCD.

ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Add rows as needed for each employment relationship.

Company	*Description*	*End Date*	*For ASH Internal Use*

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

☒ No

☐ Yes, as described below:

Add rows as needed for each equity interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Add rows as needed for each patent or royalty interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No

☒ Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.'

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each activity.

Company	*Description*	*End Date*	*For ASH Internal Use*
Hilton Publishing, Inc (http://www.hiltonpub.com/bookstore/aboutus.aspx)	I served as a consultant for this company on their NIH grant – see details of the award below. **PINPOINT grant project (Federal Award # 1R43MD010746-01), for the development of gaming technology to engage adolescent sickle cell patients in precision pain management, has been awarded by the National Institute on Minority Health and Health Disparities (NIMHD).**	9/2016 when the NIH grant ended	Not a conflict. Ended before appointment and Hilton Publishing is not an affected company for this guideline.

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

☒ No

☐ Yes, as described below:

Add rows as needed for each interest.

Company	*Description*	*End Date*	*For ASH Internal Use*

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☒ No

   ☐ Yes, as described below:

   Column 1 Name the company funding or supporting the research.

   Column 2 Briefly describe the research project.

   Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

   Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

   Add rows as needed for each research project.

Company	*Description of Research*	*My Role*	*End Date*	*For ASH Internal Use*

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces,

markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each organization.

Organization	*Description and role*	*Paid or Unpaid?*	*End Date*	*For ASH Internal Use*

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Stem Cell Transplantation for Sickle Cell Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

   ☐ No

   ☒ Yes

   If yes, please explain: I believe there is a need for continued up to date guidelines for the care of patients with sickle cell disease.

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

   ☒ No

   ☐ Yes

   If yes, what were those views and where were they made?

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

☐ No

☒ Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

Funder	*Description of Research*	*My Role*	*End Date*
NHLBI	Ancillary trial to assess health related quality of life of children admitted to the hospital for an acute vaso-occlusive crises	PI	5/2015
NIAMS	-Assessment of patient reported outcomes using the NIH PROMIS in children with sickle cell disease, asthma, and type 1 diabetes -Determination of the psychometric properties of the new domains of Pediatric PROMIS in children with sickle cell disease, asthma, and type 1 diabetes	PI	8/2019
HRSA	To improve the care of patients with sickle cell disease	Site PI	9/2017

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

   ☐ Don't know

   ☒ No

   ☐ Yes

   If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

   ☐ Don't know

   ☒ No

   ☐ Yes

   If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

   ☐ Don't know

   ☒ No

   ☐ Yes

   If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

   I would be supported by my mentors, institution, and colleagues given the important nature of the guidelines.

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

☒ No

☐ Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

Organization	*Relevant Policy Position*	*Your Role*

Clinical Practice

9. Do you see patients clinically?

☐ No

☒ Yes

If yes, what is your primary specialty or subspecialty?

Pediatric Hematology

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

☐ No

☒ Yes

If yes, please explain: I provide care to patients with sickle cell disease both in the hospital and the clinic setting. I follow recommended standards of care for these patients and expect the guidelines will address most aspects of care I am involved in clinically day to day in my care of these patients.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

☒ No

☐ Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
n/a	Site PI on research funded by the Health Resources and Services Administration (HRSA) to improve the care of patients with sickle cell disease	12/28/17	HRSA is a U.S. federal agency. Dr. Panepinto explained that grant renewal was requested by the main PI (located in Cincinnati) and has been renewed by HRSA, and the research will now end in 2021.
n/a	Site PI on research funded by the Health Resources and Services Administration (HRSA) to improve the care of patients with sickle cell disease	12/27/18	Update: the funding for this will end 09/2020 instead of 2021.
n/a	Co-Principal Investigator for National Heart Lung and Blood Institute (NHLBI), 1U01HL143477-01 Implementation of evidence-based care for the acute treatment of sickle cell disease pain. End date, 08/2020.	12/27/18	NHLBI is a U.S. federal agency.
n/a	Co-investigator for National Heart Lung and Blood Institute (NHLBI), 1 R01 HL142657-01	12/27/18	NHLBI is a U.S. federal agency.

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
	Investigating the role of the microbiome and inflammation in acute and chronic pain in patients with sickle cell disease. End date: 07/2023		
Doris Duke Charitable Foundation	COVID and Sickle cell disease: The SECURE-SCD Registry-support for the registry and addition of patients from Ghana, Africa	9/11/2020	The Doris Duke Charitable Foundation is a501(c)3 organization that provides funding to organizations in various arenas, including medical research. They do not market any products used in the diagnosis or treatment of SCD.
NIH, NINDS	The Inflammatory Index as a Biomarker for Pain in Patients with Sickle Cell Disease. Dr. Panepinto is co-PI	9/11/2020	NIH is a U.S. federal agency.
NIH, NHLBI	Implementation of evidence based care for the acute treatment of sickle cell disease pain. Dr. Panepinto is co-PI.	9/11/2020	NHLBI is a U.S. federal agency.
HRSA	Sickle Cell Disease Treatment Demonstration Project, Sickle Treatment and Outcomes Research in the Midwest (STORM). Dr. Panepinto is site PI. This is an extension of previous funding (see above).	9/11/2020	HRSA is a U.S. federal agency.

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH Guideline Panel on Stem Cell Transplantation for Sickle Cell Disease

Summary of ASH Judgments About Financial Conflicts

Reviewer name and date	*Direct Financial Conflicts?*	*Indirect Financial Conflicts?*	*Management Notes*
Webb 2/23/17; Pai 3/13/17	No	No	
Webb 2/14/18; Kunkle 2/20/18	No	No	New disclosure. See Part D above. "Other notes" added below.
Webb 12/27/18	No	No	New disclosure. See Part D above. "Other notes" added below.
Alexander 9/28/2020	No	No	New disclosures. See Part D. On 9/11/2020, Dr. Panepinto confirmed all information in this form.

Summary of Direct Financial Conflicts

Company	*Description*	*Disclosure Date*	*ASH Notes*

Other Notes

Dr. Panepinto is a specialist in pediatric hematology. In her clinical practice, she provides care to patients with sickle cell disease both in the hospital and the clinic setting. She is the principal investigator for research about patient-reported outcomes in children with SCD, funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, and she is a site investigator for research to improve the care of patients with SCD, funded by the Health Resources and Services

Administration (HRSA). She was previously the principal investigator for research related to SCD and vaso-occlusive crises, funded by HRSA. Dr. Panepinto is the co-principal investigator for research on the implementation of evidence-based care for the acute treatment of sickle cell disease pain, funded by the National Heart Lung and Blood Institute (NHLBI); and a co-investigator for research investigating the role of the microbiome and inflammation in acute and chronic pain in patients with sickle cell disease, also funded by NHLBI.

ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☒ No

   ☐ Yes, as described below:

   Add rows as needed for each employment relationship.

Company	*Description*	*End Date*	*For ASH Internal Use*

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

   ☒ No

   ☐ Yes, as described below:

   Add rows as needed for each equity interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☒ No

   ☐ Yes, as described below:

   Add rows as needed for each patent or royalty interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☐ No

   ☒ Yes, as described below:

   Column 1 Name the company.

   Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each activity.

Company	*Description*	*End Date*	*For ASH Internal Use*
Sanofi	Speaker Bureau involvement	2015	Ended before appointment.
Incyte	Service in advisory board on Jakafi	2015	Ended before appointment.
Janssen	Service in advisory board for chronic GVHD drug Ibritnib.	1/2017	Ended before appointment.

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

☒ No

☐ Yes, as described below:

Add rows as needed for each interest.

Company	*Description*	*End Date*	*For ASH Internal Use*

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☒ No

   ☐ Yes, as described below:

   Column 1 Name the company funding or supporting the research.

   Column 2 Briefly describe the research project.

   Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

   Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

   Add rows as needed for each research project.

Company	*Description of Research*	*My Role*	*End Date*	*For ASH Internal Use*

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces,

markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each organization.

Organization	*Description and role*	*Paid or Unpaid?*	*End Date*	*For ASH Internal Use*

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Stem Cell Transplantation for Sickle Cell Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

   ☒ No

   ☐ Yes

   If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

   ☒ No

   ☐ Yes

   If yes, what were those views and where were they made?

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

   ☒ No

☐ Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

Funder	*Description of Research*	*My Role*	*End Date*

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

☐ Don't know

☒ No

☐ Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

☐ Don't know

☒ No

☐ Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

   ☐ Don't know

   ☒ No

   ☐ Yes

   If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution? My institution would fully support me since our university leaders would trust my evidence-based scientific position and they trust fully an organization such as ASH.

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

   ☒ No

   ☐ Yes, as described below:

   Column 1 Name the organization.

   Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

   Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

   Add rows as needed for each organization.

Organization	*Relevant Policy Position*	*Your Role*

Clinical Practice

9. Do you see patients clinically?

☐ No

☒ Yes

If yes, what is your primary specialty or subspecialty?

Blood and Marrow Transplantation and hematology

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

☐ No

☒ Yes

If yes, please explain:

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

☒ No

☐ Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
Incyte	Principal Investigator on INCB 18424-365- A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid – refractory chronic graft versus host disease after allogenic stem cell transplantation Dates: 08/29/2017-08/28/2022	1/9/19	Indirect conflict. Incyte is investigating a variety of targeted therapies for cancer and other conditions. Two products (Ruxolitinib and Itacitinib) in development are for graft-vs-host disease; a post-transplant complication relevant but not specific to SCD patients. These products are not yet to market and will not be addressed in this guideline; however, the company could be indirectly affected by recommendations on transplant since patients with successful transplants would not be candidates for these products.
Incyte	Principal Investigator on INCB 39110-301 GRAVITAS-301: A Randomized, Double-blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination with Corticosteroids for the Treatment of First-Line	1/9/19	Indirect conflict. See above.

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
	Acute Graft-Versus-Host Disease Dates: 03/01/2018-02/28/26		
Alexion Pharmaceuticals	Received direct transfers of value (food and beverage) for attending a meeting in 2016.	1/14/19	Ended before appointment.
Seattle Genetics	Received direct transfers of value (food and beverage) for attending a meeting in 2016 or 2017.	1/14/19	Not a conflict. Seattle Genetics does not have any products that could be affected by this guideline.
Vertex Pharmaceuticals	CTX001 gene therapy clinical trail in sickle cell disease at UIC. Dr. Rondelli was appointed PI of this trial in 2018. As of 9/11/2020, not patients have been enrolled and no money has been given to the institution. Dr. Rondelli has also received direct payments for serving on a steering committee for this trial.	9/11/20	Indirect conflict. Vertex Pharmaceuticals is developing CTX001 (a gene therapy) for treatment of sickle cell disease. Although gene therapy will not be addressed in this guideline, the company could be indirectly affected by recommendations about transplantation because gene therapy is being developed as an alternative treatment to transplantation.

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH Guideline Panel on Stem Cell Transplantation for Sickle Cell Disease

Summary of ASH Judgments About Financial Conflicts

Reviewer name and date	*Direct Financial Conflicts?*	*Indirect Financial Conflicts?*	*Management Notes*
Webb 3/9/17 Pai 3/13/17; Webb 2/14/18	No	No	
Webb 1/14/19	No	Yes	New disclosure. See Part D. above. Dr. Rondelli is the Principal Investigator on research funded by Incyte. The company could be indirectly affected by this guideline as it is developing therapies for graft-vs-host disease. Funding for the research projects goes to Dr. Rondelli's institution, not to him directly. These indirect conflicts will be managed through disclosure and panel composition. Recusal will not be required.
Alexander 9/28/2020	No	Yes	New disclosure. See Part D. On 9/11/2020, Dr. Rondelli confirmed all information in this form.

Summary of Direct Financial Conflicts

Company	*Description*	*Disclosure Date*	*ASH Notes*

Other Notes

Dr. Rondelli specializes in hematology and blood and marrow transplantation.

ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Add rows as needed for each employment relationship.

Company	*Description*	*End Date*	*For ASH Internal Use*

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

☒ No

☐ Yes, as described below:

Add rows as needed for each equity interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Add rows as needed for each patent or royalty interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No

☒ Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each activity.

Company	*Description*	*End Date*	*For ASH Internal Use*
Vertex Pharmaceuticals Inc	Advisory Board Meeting	November 7, 2016	Ended before appointment.

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

☒ No

☐ Yes, as described below:

Add rows as needed for each interest.

Company	*Description*	*End Date*	*For ASH Internal Use*

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☐ No

   ☒ Yes, as described below:

   Column 1 Name the company funding or supporting the research.

   Column 2 Briefly describe the research project.

   Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

   Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

   Add rows as needed for each research project.

Company	*Description of Research*	*My Role*	*End Date*	*For ASH Internal Use*
Therakos	Participating in clinical trial for treatment of GVHD	Site PI	Ongoing	Indirect conflict. Therakos (owned by Mallinckrodt Pharmaceuticals) is developing a treatment for GVHD. Although the product will not be addressed in this guideline, the company could be indirectly affected by recommendations about transplantation because GVHD is a post-transplant complication.
Mesoblast	Participating in clinical trial for the treatment of GVHD	Site PI	Ongoing	Indirect conflict. Mesoblast is developing a treatment for GVHD. Although the product will not be addressed in this guideline, the company could be indirectly affected by recommendations about transplantation because GVHD is a post-transplant complication.

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces,

markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each organization.

Organization	*Description and role*	*Paid or Unpaid?*	*End Date*	*For ASH Internal Use*
Gamida Cell	DSMB clinical trial for in vitro expanded cord blood transplantation for sickle cell disease	Unpaid	Projected end date 2018	Not a conflict. Gamida Cell sells cord blood stem cells for profit. These guidelines will provide recommendations about when to do stem cell transplantation in patients with SCD but will not address stem cell source, either as a specific recommendation or as an aspect of implementation. (If this changes, Gamida Cell will be considered an affected company, and this research activity will be considered an indirect conflict.)
Boston Children's Hospital	DSMC member on a clinical trial of the use of plerixafor for stem cell	Fee per year for serving on	Has not started	Not a conflict. Boston Children's Hospital is

Organization	*Description and role*	*Paid or Unpaid?*	*End Date*	*For ASH Internal Use*
	mobilization in patients with sickle cell disease	the DSMC after enrollment begins	enrolling yet	not an affected company.
University of Cincinnati	DSMB gene therapy trial for sickle cell disease	Fee per year for serving on the DSMC after enrollment begins	ongoing	Not a conflict. University of Cincinnati is not an affected company.
NYSTEM New York State Stem Cell Science	Member of review panel for a grant awarded to the Weill-Cornell Medical Center and MSKCC by NYSTEM for the development of gene therapy for sickle cell disease	Travel paid per diem to attend in person review meetings. American Institute of Biological Sciences provides Honorarium for meeting attendance and progress review.	2019	Not a conflict. NYSTEM New York State Stem Cell Science is not an affected company. American Institute of Biological Sciences is not an affected company.

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☒ No

   ☐ Yes

   If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

ASH Guideline Panel on Stem Cell Transplantation for Sickle Cell Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

   ☐ No

   ☒ Yes

   If yes, please explain: I am interested in defining guidelines for sickle cell disease transplants in the changing environment of the treatment for this disease. I have advocated for performing sickle cell disease transplants under the umbrella of formal clinical trials so that outcomes are tracked and reported.

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

   ☐ No

   ☒ Yes

   If yes, what were those views and where were they made?

   I have addressed transplantation for sickle cell disease in talks and review articles and have published results of clinical trials. As stated above, I have advocated for performing sickle cell disease transplants under the umbrella of formal clinical trials so that outcomes are tracked and reported.

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

☐ No

☒ Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

Funder	*Description of Research*	*My Role*	*End Date*
NHLBI via the BMT CTN	Unrelated donor transplantation for severe sickle cell disease	PI	Study follow up completed in 2016
Children's Discovery Institute, Washington University in St. Louis	Mismatched donor transplantation for non-malignant disorders including sickle cell disease	PI	June 2019

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

☐ Don't know

☒ No

☐ Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

   ☐ Don't know

   ☒ No

   ☐ Yes

   If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

   ☐ Don't know

   ☒ No

   ☐ Yes

   If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

   I have addressed the topic previously. I am not aware of any change in support positive or negative that might be generated from this activity.

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

   ☒ No

   ☐ Yes, as described below:

   Column 1 Name the organization.

   Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

Organization	*Relevant Policy Position*	*Your Role*
Boston Children's Hospital	I have been asked for an opinion on a clinical case related to a sickle cell disease transplant by legal counsel on behalf of the hospital	Provided an opinion after reviewing records.

Clinical Practice

9. Do you see patients clinically?

☐ No

☒ Yes

If yes, what is your primary specialty or subspecialty?

Pediatric hematology oncology and transplant

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

☐ No

☒ Yes

If yes, please explain:

I see patients with sickle cell disease referred for transplant, determine eligibility and enroll on relevant clinical transplant trials if considered eligible.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

☒ No

☐ Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
Jazz Pharmaceuticals	Dr. Shenoy received direct payment for serving on an Advisory Board in December 2018. She facilitated a discussion regarding recognition and treatment of hepatic sinusoidal obstruction syndrome.	12/26/18	Indirect conflict. Jazz Pharmaceuticals markets defitelio for treatment of sinusoidal obstruction syndrome with renal or pulmonary dysfunction following hematopoietic stem cell transplantation. This product will not be addressed in this guideline. However, the company could be indirectly affected by recommendations on transplant since patients with successful transplants may not be candidates for these products.
Magenta Therapeutics	Dr. Shenoy is a Site PI on a clinical trial of umbilical cord blood transplant following in vitro expansion for sickle cell disease. The trial is expected to begin in the latter half of 2019, and last 12-18 months.	12/26/18	Indirect conflict. Magenta Therapeutics is developing gene and cell technologies and therapeutics, including for use in stem cell transplantation for SCD. The company is also in the early stages of developing an SCD clinical trial (trial not yet open) using expanded umbilical cord blood for transplantation. Although these guidelines will address

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
			stem cell transplantation and cord blood use, these products are not yet to market and will not be addressed in this guideline. The company could be indirectly affected by recommendations on transplantation since SCD patients receiving transplants would be candidates for these technologies and therapy.
Bluebird bio	Direct payment for serving on Advisory Board, September 2017.	1/14/19	Indirect conflict. Bluebird Bio is developing a gene editing platform for use in SCD patients. Although gene therapy will not be addressed in this guideline, the company could be indirectly affected by recommendations about transplantation because gene therapy is being developed as an alternative treatment to transplantation.
Vertex	Direct payment for serving on Advisory Board, December 2017.	1/14/19	Indirect conflict. Vertex and CRISPR Therapeutics is developing CTX001 a gene edited hematopoietic stem cell therapy for use in SCD patients. Although gene therapy will not be addressed in this guideline, the company could be indirectly

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
			affected by recommendations about transplantation because gene therapy is being developed as an alternative treatment to transplantation.
Novartis	Direct payment for serving on Advisory Board, February 2017.	1/14/19	Ended before appointment.
n/a	The American Society of Pediatric Hematology/Oncology (ASPHO)/Pediatric Blood and Marrow Transplant Consortium (PBMTC) Bone Marrow Transplant Day – Organizing Chair – Clinical Events	1/14/19	Not a conflict. The American Society of Pediatric Hematology/Oncology is a nonprofit organization. Pediatric Blood and Marrow Transplant Consortium is a not for profit consortium.
Bard Pharmaceuticals	Dr. Shenoy reported that her spouse served on an Advisory Board for Bard.	1/14/19	Not a conflict. Bard markets various products for vascular urology, oncology and surgical management. These products will not be specifically addressed in these guidelines.
Therakos	Participating in clinical trial for treatment of GVHD. This study has closed.	9/17/20	This is an update to Part B, Question 1.
Mesoblast	Participating in clinical trial for treatment of GVHD. This study has closed.	9/17/20	This is an update to Part B, Question 1.
Aruvant	Chair of DSMB gene therapy trial for		Indirect conflict. This is an update to Part B,

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
	sickle cell disease. This trial was formerly run by the University of Cincinnati and was taken over by Aruvant.		Question 2. Aruvant is developing a gene therapy for treatment of sickle cell disease. Although gene therapy will not be addressed in this guideline, the company could be indirectly affected by recommendations about transplantation because gene therapy is being developed as an alternative treatment to transplantation,
Gamida Cell	DSMB clinical trial for in vitro expanded cord blood transplantation for sickle cell disease. This study has closed.	9/17/2020	This is an update to Part B, Question 2.
Gerson Lehrman Group	Direct payment for consulting on sickle cell disease	9/17/2020	Not a conflict. GLG is consulting group that provides consulting services to several industries, including pharmaceutical companies. GLG does not market any products used in the diagnosis or treatment of sickle cell disease.
California Institute of Regenerative Medicine	Clinical advisor for the California Institute of Regenerative Medicine. This activity started in August 2020.	9/17/2020	Not a conflict. CIRM provides funding for stem cell research to academic centers and companies. CIRM does not conduct research. They do not market any products related to treatment of SCD.

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH Guideline Panel on Stem Cell Transplantation for Sickle Cell Disease

Summary of ASH Judgments About Financial Conflicts

Reviewer name and date	*Direct Financial Conflicts?*	*Indirect Financial Conflicts?*	*Management Notes*
Webb 3/7/17; Pai 3/13/17; Webb 1/4/18; Kunkle 2/6/18; Lottenberg 2/6/18	No	Yes	Dr. Shenoy has research funding from Therakos and Mesoblast. Both companies are developing GVHD products, which might be indirectly affected by recommendations about transplantation. Funding for these research projects goes to Dr. Shenoy's' institution, not to her directly. These indirect conflicts will be managed by disclosure and by panel composition. Recusal will not be required. Dr. Shenoy is also involved in research funded by Gamida Cell. This company stores and sells cord blood stem cells for profit. These guidelines will provide recommendations about when to do stem cell transplantation in patients with SCD but will not address stem cell source, either as a specific recommendation or as an aspect of implementation. (If this changes, Gamida Cell will be considered affected, and Dr. Shenoy's research activity will be considered an indirect conflict.)
Webb 1/15/19	No	Yes	New disclosures. See Part D. above. Dr. Shenoy reports receiving direct payments from Jazz Bluebird bio, and Vertex. These companies are developing products for graft-vs-host disease or gene therapy and could be indirectly affected by this guideline. Dr. Shenoy also expects to begin a Site PI role with Magenta, a company that is developing gene and cell technologies and investigating umbilical cord blood use in SCD transplantation. This company could also be indirectly affected by this guideline.

			Funding for the research project would go to Dr. Shenoy's institution, not to her directly. These indirect conflicts will be managed through disclosure and panel composition. Recusal will not be required.
Alexander 9/28/2020			New disclosures. See Part D. On 9/17/2020, Dr. Shenoy confirmed all information in this form.

Summary of Direct Financial Conflicts

Company	*Description*	*Disclosure Date*	*ASH Notes*

Other Notes

Dr. Shenoy is the principal investigator on research about transplantation for SCD funded by the National Heart, Lung and Blood Institute and by the Children's Discovery Institute. She reports that she has addressed the topic of transplant for SCD in talks and review articles. Dr. Shenoy specializes in pediatric hematology, oncology, and transplant. She sees patients with SCD who are referred for transplant, determines eligibility, and enrolls patients in trials. Dr. Shenoy serves as the Organizing Chair of the clinical events committee for the American Society of Pediatric Hematology/Oncology-Pediatric Blood and Marrow Transplant Consortium's Bone Marrow Transplant Day.

ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☒ No

   ☐ Yes, as described below:

   Add rows as needed for each employment relationship.

Company	*Description*	*End Date*	*For ASH Internal Use*

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

   ☒ No

   ☐ Yes, as described below:

Add rows as needed for each equity interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Add rows as needed for each patent or royalty interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each activity.

Company	*Description*	*End Date*	*For ASH Internal Use*

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

☒ No

☐ Yes, as described below:

Add rows as needed for each interest.

Company	*Description*	*End Date*	*For ASH Internal Use*

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☒ No

   ☐ Yes, as described below:

   Column 1 Name the company funding or supporting the research.

   Column 2 Briefly describe the research project.

   Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

   Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

   Add rows as needed for each research project.

Company	*Description of Research*	*My Role*	*End Date*	*For ASH Internal Use*

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces,

markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each organization.

Organization	*Description and role*	*Paid or Unpaid?*	*End Date*	*For ASH Internal Use*

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

ASH Guideline Panel on Stem Cell Transplantation for Sickle Cell Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

   ☒ No

   ☐ Yes

   If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

   ☐ No

   ☒ Yes

   If yes, what were those views and where were they made?

   BLOOD, 2011, Aug 4; 118(5) 1197-207

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

   ☐ No

☒ Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

Funder	*Description of Research*	*My Role*	*End Date*
NIH	Transplant for SCD	P.I.	No end date

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

☐ Don't know

☒ No

☐ Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

☐ Don't know

☒ No

☐ Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

☐ Don't know

☒ No

☐ Yes

If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

My support is merit based and I am tenured in the federal government and this would not change.

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

☒ No

☐ Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

Organization	*Relevant Policy Position*	*Your Role*

Clinical Practice

9. Do you see patients clinically?

☐ No

☒ Yes

If yes, what is your primary specialty or subspecialty?

Hematology

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

☐ No

☒ Yes

If yes, please explain:

I perform bone marrow transplants in sickle cell disease.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

☒ No

☐ Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
Sanofi and Genzyme US Companies	Dr. Tisdale is the Principal Investigator on an SCD study where Sanofi Genzyme donated the drug Plerixafor to the National Heart Lung and Blood Institute (NHLBI) on 7/20/2017.	1/8/2019	Very indirect conflict. Dr. Tisdale reports no funding was received by him or his institution. Sanofi markets plerixafor to prepare blood for hematopoietic stem cell transplant. In addition, Bioverativ, which was acquired by Sanofi in 2018, is developing a gene therapy for SCD. Neither plerixafor nor gene therapy will be addressed in this guideline. However, the company could be indirectly affected by recommendations on transplant since patients could receive plerixafor pre-transplant and because gene therapy is being developed as an alternative treatment to transplantation.

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH Guideline Panel on Stem Cell Transplantation for Sickle Cell Disease

Summary of ASH Judgments About Financial Conflicts

Reviewer name and date	*Direct Financial Conflicts?*	*Indirect Financial Conflicts?*	*Management Notes*
Webb 8/26/16, Kunkle 8/26/16; Webb 1/9/18	No	No	
Webb 1/16/19	No	Yes	New disclosures. See Part D. above. This very indirect conflict will be managed through disclosure and panel composition.
Alexander 10/27/1010	No	Yes	On 9/24/2020, Dr. Tisdale confirmed all information in this form.

Summary of Direct Financial Conflicts

Company	*Description*	*Disclosure Date*	*ASH Notes*

Other Notes

Dr. Tisdale is a hematologist and researcher at the National Institutes of Health (NIH) who treats patients with SCD using bone marrow transplantation. He is the principal investigator on NIH research about transplant for SCD patients. He has published opinions and reviews about this topic.

ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☒ No

   ☐ Yes, as described below:

   Add rows as needed for each employment relationship.

Company	*Description*	*End Date*	*For ASH Internal Use*

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

   ☒ No

   ☐ Yes, as described below:

   Add rows as needed for each equity interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Add rows as needed for each patent or royalty interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No

☒ Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each activity.

Company	*Description*	*End Date*	*For ASH Internal Use*
Novartis	Consultancy	May 2015	Ended before appointment.
Novartis	Consultancy	November 2015	Ended before appointment.
CORD:USE	Scientific Advisor	Ongoing	Not a conflict. CORD:USE stores and sells cord blood stem cells for profit. These guidelines will provide recommendations about when to do stem cell transplantation in patients with SCD but will not address stem cell source, either as a specific recommendation or as an aspect of implementation. (If this changes, CORD:USE will be considered an affected company, and Dr. Wagner's paid relationship with the company will be considered a direct financial conflict requiring recusal.)
VidaCord	Scientific Advisor	Ongoing	Not a conflict. VidaCord stores and sells cord blood stem cells for profit. These guidelines will provide recommendations about when to do stem cell transplantation in patients with SCD but will not address stem cell source, either as a

Company	*Description*	*End Date*	*For ASH Internal Use*
			specific recommendation or as an aspect of implementation. (If this changes, VidaCord will be considered an affected company, and Dr. Wagner's paid relationship with the company will be considered a direct financial conflict requiring recusal.)

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

☒ No

☐ Yes, as described below:

Add rows as needed for each interest.

Company	*Description*	*End Date*	*For ASH Internal Use*

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☐ No

   ☒ Yes, as described below:

   Column 1 Name the company funding or supporting the research.

   Column 2 Briefly describe the research project.

   Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

   Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

   Add rows as needed for each research project.

Company	*Description of Research*	*My Role*	*End Date*	*For ASH Internal Use*

Novartis	Use of StemRegenin-1 to expand Hematopoietic Stem Cells in Cord Blood Phase I-II Testing	PI	Enrollment ended 2016 Follow up work ended 11/2023	Indirect conflict. This research is on hematological malignancies, not SCD. However, Novartis could be indirectly affected by this guideline: Novartis is partnering with Intellia Therapeutics to develop a gene editing platform for treatment of SCD. Novartis also markets deferasirox and deferoxamine for iron overload and is developing crizanlizumab to prevent vaso-occlusive crisis. Although neither gene therapy nor crizanlizumab will be addressed in this guideline, the company could be indirectly affected by recommendations about transplantation because gene therapy is being developed as an alternative treatment to transplantation and because patients with successful transplants would not be candidates for crizanlizumab. Usage of iron overload products could be indirectly affected by recommendations about transplant since in SCD, the

Company	*Description of Research*	*My Role*	*End Date*	*For ASH Internal Use*
				major cause of iron overload is red blood cell transfusion – transplantation can influence the need for transfusion (pre-transplant and dependent on the outcome of transplant) as well as use of iron chelator therapy.
Gamida Cell	Use of NiCord in Phase 2 Trial	PI	Enrollment ended 2/2017 Follow up will end 2/2018	Not a conflict. Gamida Cell sells cord blood stem cells for profit. These guidelines will provide recommendations about when to do stem cell transplantation in patients with SCD but will not address stem cell source, either as a specific recommendation or as an aspect of implementation. (If this changes, Gamida Cell will be considered an affected company, and Dr. Wagner's leadership role on this research study will be considered an indirect financial conflict.) Note: this research is on hematological malignancies, not SCD.

Company	*Description of Research*	*My Role*	*End Date*	*For ASH Internal Use*

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each organization.

Organization	*Description and role*	*Paid or Unpaid?*	*End Date*	*For ASH Internal Use*

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☒ No

   ☐ Yes

   If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

ASH Guideline Panel on Stem Cell Transplantation for Sickle Cell Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

   ☒ No

   ☐ Yes

   If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

   ☒ No

   ☐ Yes

   If yes, what were those views and where were they made?

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

   ☒ No

☐ Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

Funder	*Description of Research*	*My Role*	*End Date*

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

☐ Don't know

☒ No

☐ Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

☐ Don't know

☒ No

☐ Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

☐ Don't know

☒ No

☐ Yes

If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I do not believe that there would be any impact positive or negative.

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

☒ No

☐ Yes, as described below:

Column 1 Name the organization.

Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

Add rows as needed for each organization.

Organization	*Relevant Policy Position*	*Your Role*

Clinical Practice

9. Do you see patients clinically?

☐ No

☒ Yes

If yes, what is your primary specialty or subspecialty?

Blood and Marrow Transplant
Pediatrics

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

☐ No

☒ Yes

If yes, please explain:

These guidelines will likely lead to best practice that on how to best counsel and treat patients with sickle cell disease. For example, the guidelines could better define which patients should be considered optimal candidate for BMT vs other existing or emerging therapy (e.g. gene therapy)

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

☒ No

☐ Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
Magenta	Direct payment for consultant role (the contract is being finalized). Will be responsible for developing a protocol to improve the engraftment rate in SCD patients receiving bone marrow transplants.	2/15/2018	Indirect conflict. Magenta Therapeutics is developing gene and cell technologies and therapeutics, including for use in stem cell transplantation for SCD. Although these guidelines will address stem cell transplantation, these products are not yet to market and the above modalities will not be addressed in these guidelines. The company could be indirectly affected by recommendations on transplantation since SCD patients receiving transplants would be candidates for these technologies and therapies.
Magenta	As described in an email from Dr. Wagner: he has a university contract to develop the clinical trials for hematological malignancy and inborn errors of metabolism at his institution. Since he is taking on the consultant role with Magenta, he cannot be PI of the trials. Three of	2/15/2018	Indirect conflict. As described above, Magenta Therapeutics could be indirectly affected by these guidelines.

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
	his colleagues will take on the role of PI and Co-PIs for the two trials.		
Gamida Cell	Dr. Wagner was previously the PI of a phase III trial for the use of Nicord. He reports that the study is still ongoing however he is no longer on the study as of 9/1/18.	12/22/18	Not a conflict as noted above.
Magenta	Dr. Wagner reports receiving stock options beginning in June 2018 for his role as a clinical consultant. He is working with the company to develop a new antibody as a way pf replacing chemotherapy agents before transplant. He is also in the early stages of discussing a potential clinical trial for cord blood and SCD transplant.	12/22/18	Indirect conflict as noted above. In addition, Magenta is also in the early stages of developing an SCD clinical trial (trial not yet open) using expanded umbilical cord blood for transplantation.

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH Guideline Panel on Stem Cell Transplantation for Sickle Cell Disease

Summary of ASH Judgments About Financial Conflicts

Reviewer name and date	*Direct Financial Conflicts?*	*Indirect Financial Conflicts?*	*Management Notes*
Webb 3/9/17; Pai 3/13/17; Webb 12/19/17; Alexander 1/10/18; Kunkle 2/6/18; Lottenberg 2/6/18	No	Yes	Dr. Wagner has research that is funded by Novartis, which is developing a disease-modifying therapy for SCD that could be viewed as competitive with transplantation. Novartis also markets products used for iron overload. Funding for the research project goes to Dr. Wagner's institution, not to him directly. This indirect conflict will be managed through disclosure and panel composition. Recusal will not be required. Dr. Wagner also reports direct payments from CORD:USE and VidaCord, and he is the principal investigator on research funded by Gamida Cell. All of these companies store and sell cord blood stem cells for profit. These guidelines will provide recommendations about when to do stem cell transplantation in patients with SCD but will not address stem cell source, either as a specific recommendation or as an aspect of implementation. (If this changes, the companies will be considered affected, and Dr. Wagner's paid activities for the companies will be considered a direct financial conflict requiring recusal.)
Webb 2/15/18; Lottenberg 2/23/18	No	Yes	New disclosure. See Part D above. Dr. Wagner is receiving direct payments from Magenta Therapeutics, which is developing gene and cell technologies and therapeutics for use in stem cell transplantation. These guidelines will not provide recommendations on the use of these modalities.

			This indirect conflict will be managed through disclosure and panel composition. Recusal will not be required.
Webb 1/14/19	No	Yes	New disclosure. See Part D above. Dr. Wagner reports receiving direct payments (stock) from Magenta Therapeutics, which is developing gene and cell technologies and investigating umbilical cord blood use in SCD transplantation. This company could also be indirectly affected by this guideline. This indirect conflict will be managed through disclosure and panel composition. Recusal will not be required.
Webb 2/4/19; Lottenberg 2/4/19	Yes	Yes	Dr. Wagner should have been recused for his direct financial relationships with VidaCord, CORD:USE, and Gamida Cell. However, he is in the minority of the panel and ASH is comfortable with how these conflicts were managed during the meeting through panel composition and disclosure.
Alexander 9/28/20	Yes	Yes	On 9/11/2020, Dr. Wagner confirmed all information in this form.

Summary of Direct Financial Conflicts

Company	*Description*	*Disclosure Date*	*ASH Notes*

Other Notes

Dr. Wagner is a pediatric hematologist/oncologist. In his clinical practice, he treats patients with SCD using bone marrow transplantation.

ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Add rows as needed for each employment relationship.

Company	*Description*	*End Date*	*For ASH Internal Use*

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

☒ No

☐ Yes, as described below:

Add rows as needed for each equity interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Add rows as needed for each patent or royalty interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No

☒ Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each activity.

Company	*Description*	*End Date*	*For ASH Internal Use*
Bluebird bio, Inc	Scientific Advisory	Dec 2015	Ended before appointment.
Baxter	honorarium	Nov 2015	Ended before appointment.
Kiadis Pharma	consultant	Feb 2016	Ended before appointment.

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

☒ No

☐ Yes, as described below:

Add rows as needed for each interest.

Company	*Description*	*End Date*	*For ASH Internal Use*

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☐ No

   ☒ Yes, as described below:

   Column 1 Name the company funding or supporting the research.

   Column 2 Briefly describe the research project.

   Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

   Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

   Add rows as needed for each research project.

Company	*Description of Research*	*My Role*	*End Date*	*For ASH Internal Use*
Bluebird bio, Inc	Gene therapy trials	PI	ongoing	Indirect conflict. Bluebird Bio is developing a gene editing platform for use in SCD patients. Although gene therapy will not be addressed in this guideline, the company could be indirectly affected by recommendations about transplantation because gene therapy is being developed as an alternative treatment to transplantation.

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☐ No

☒ Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each organization.

Organization	*Description and role*	*Paid or Unpaid?*	*End Date*	*For ASH Internal Use*
ViaCord Processing Lab	Medical director	paid	ongoing	Not a conflict. ViaCord stores and sells cord blood stem cells for profit. These guidelines will provide recommendations about when to do stem cell transplantation in patients with SCD but will not address stem cell source, either as a specific recommendation or as an aspect of implementation. (If this changes, ViaCord will be considered an affected company, and Dr. Walters' role as a paid medical director will be considered a direct financial conflict requiring recusal.)
AllCells, Inc	Medical director	paid	ongoing	Not a conflict. AllCells stores and sells cord blood stem cells for profit. These guidelines will provide recommendations about when to do stem cell transplantation in patients with SCD but will not address stem cell source, either as a specific

Organization	*Description and role*	*Paid or Unpaid?*	*End Date*	*For ASH Internal Use*
				recommendation or as an aspect of implementation. (If this changes, AllCells will be considered an affected company, and Dr. Walters' role as a paid medical director will be considered a direct financial conflict requiring recusal.)

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☒ No

   ☐ Yes

   If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

ASH Guideline Panel on Stem Cell Transplantation for Sickle Cell Disease

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

   ☒ No

   ☐ Yes

   If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

   ☐ No

   ☒ Yes

   If yes, what were those views and where were they made?

   Peer-reviewed review articles in Curr Opin Heme and BBMT in the past 2 years in support of HCT for SCD as a therapeutic option that should be considered in children with a HLA-ID sib donor.

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

   ☐ No

☒ Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

Funder	*Description of Research*	*My Role*	*End Date*
NHLBI	BMT for adults with SCD	Co-PI	2020
CIRM	Genomic editing for SCD – pre-clinical	PI	2020

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

☐ Don't know

☒ No

☐ Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

☐ Don't know

☒ No

☐ Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

   ☒ Don't know

   ☐ No

   ☐ Yes

   If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution? I think it would be a neutral reaction that would not change the current level of support.

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

   ☐ No

   ☒ Yes, as described below:

   Column 1 Name the organization.

   Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

   Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

   Add rows as needed for each organization.

Organization	*Relevant Policy Position*	*Your Role*
NHLBI	SCD advisory board	chair

Clinical Practice

9. Do you see patients clinically?

☐ No

☒ Yes

If yes, what is your primary specialty or subspecialty?

Pediatric hematology/oncology

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

☐ No

☒ Yes

If yes, please explain: I treat patients with SCD by BMT.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

☒ No

☐ Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
Editas	Dr. Walters received direct payment for consulting.	1/14/19	Indirect conflict. Editas is in the preclinical phase of using gene editing for the treatment of SCD. Although gene therapy will not be addressed in this guideline, the company could be indirectly affected by recommendations about transplantation because gene therapy is being developed as an alternative treatment to transplantation.
AllCells, Inc	Dr. Walters received direct payment for consulting.	10/27/2020	Not a conflict. AllCells stores and sells cord blood stem cells for profit. These guidelines will provide recommendations about when to do stem cell transplantation in patients with SCD but will not address stem cell source, either as a specific recommendation or as an aspect of implementation.
AllCells, Inc	Dr. Walters reports stock options in AllCells, Inc.	10/27/2020	COI. AllCells stores and sells cord blood stem cells for profit. This activity was reported after the

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
			recommendations were formed.
Veevo/Ensoma	Dr. Walters received direct payment for consulting. Starting in January 2020.	10/27/2020	Indirect conflict. Veevo is developing in vivo gene therapies for potential use in sickle cell disease. Although gene therapy will not be addressed in this guideline, the company could be indirectly affected by recommendations about transplantation because gene therapy is being developed as an alternative treatment to transplantation.
Editas Medicine	Dr. Walters received direct payment for consulingDecember 2018.	10/27/2020	Indirect conflict. Editas Medicine is developing a ex vivo gene editing medicines for use in SCD patients. Although gene therapy will not be addressed in this guideline, the company could be indirectly affected by recommendations about transplantation because gene therapy is being developed as an alternative treatment to transplantation.

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH Guideline Panel on Stem Cell Transplantation for Sickle Cell Disease

Summary of ASH Judgments About Financial Conflicts

Reviewer name and date	*Direct Financial Conflicts?*	*Indirect Financial Conflicts?*	*Management Notes*
Webb 3/3/2017; Pai 3/13/17; Webb 12/19/17; Alexander 1/10/18; Kunkle 1/31/18; Lottenberg 2/6/18	No	Yes	Dr. Walters has research that is funded by Bluebird Bio. The company is developing a disease-modifying therapy for SCD that will be competitive with transplantation. Funding for the research project goes to Dr. Walter's institution, not to him directly. This indirect conflict will be managed through disclosure and panel composition. Recusal will not be required. Dr. Walters also has a paid role as the medical director of ViaCord and AllCell. Both companies store and sell cord blood stem cells for profit. These guidelines will provide recommendations about when to do stem cell transplantation in patients with SCD but will not address stem cell source, either as a specific recommendation or as an aspect of implementation. (If this changes, ViaCord and AllCell will be considered affected companies, and Dr. Walters' paid role will be considered a direct financial conflict requiring recusal.)
Webb 1/16/19	No	Yes	New disclosures. See Part D. above. Dr. Walters reports receiving direct payment from Editas, which is developing a gene edited therapy for SCD. This company could be indirectly affected by these guidelines. These indirect conflicts will be managed through disclosure and panel composition. Recusal will not be required.

Webb 2/4/19; Lottenberg 2/4/19	Yes	Yes	Dr. Walters should have been recused for his direct financial relationships with VidaCord and AllCell. However, he is in the minority of the panel and ASH is comfortable with how these conflicts were managed during the meeting through panel composition and disclosure.
Alexander 11/2/2020	Yes	Yes	On October 27, 2020, Dr. Walters confirmed all information in this form.

Summary of Direct Financial Conflicts

Company	*Description*	*Disclosure Date*	*ASH Notes*

Other Notes

Dr. Walters treats patients with SCD using bone marrow transplantation, and as noted above, he is the medical director for two cord blood banks, ViaCord and AllCell. He has written peer-reviewed articles in support of HCT for SCD as a therapeutic option in children with a HLA-ID sibling donors. He has a leadership role on research on bone marrow transplant funded by the National Heart, Lung and Blood Institute and on genomic editing funded by the California Institute for Regenerative Medicine.

ASH Guideline Panel Declaration of Interests Form

Part A. Direct Financial Interests in or Relationships With Companies

Employment

1. Are you currently or in the past 24 months have you been an employee of any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☒ No

   ☐ Yes, as described below:

   Add rows as needed for each employment relationship.

Company	*Description*	*End Date*	*For ASH Internal Use*

Equity

2. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

   ☒ No

   ☐ Yes, as described below:

Add rows as needed for each equity interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Patents, Royalties, and Other Intellectual Property

3. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Add rows as needed for each patent or royalty interest.

Company	*Description*	*Date Divested*	*For ASH Internal Use*

Personal Income or Other Direct Transfers of Value

4. Do you currently or in the past 24 months have you received any personal income or other direct transfers of value (e.g., honoraria, gifts, travel support, meeting registration, meals) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received the income or other transfer of value, e.g., research, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each activity.

Company	*Description*	*End Date*	*For ASH Internal Use*

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests or relationships described in questions 1-4?

☒ No

☐ Yes, as described below:

Add rows as needed for each interest.

Company	*Description*	*End Date*	*For ASH Internal Use*

Part B. Indirect Financial Interests in or Relationships With Companies

Industry-Funded Institutional Research

1. Through your institution, do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support, such as provision of a study drug) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

   ☒ No

   ☐ Yes, as described below:

   Column 1 Name the company funding or supporting the research.

   Column 2 Briefly describe the research project.

   Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

   Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

   Add rows as needed for each research project.

Company	*Description of Research*	*My Role*	*End Date*	*For ASH Internal Use*

Paid and Volunteer Activities for Organizations Supported by Industry

2. Do you currently or in the past 24 months have you been involved in any volunteer or paid work for an organization that is wholly or partially funded by any for-profit company that develops, produces,

markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes, as described below:

Column 1 Name the organization. If known to you, describe any industry funding or support.

Column 2 Briefly describe your activity and role, e.g., employment, service on board of directors, other volunteer services.

Column 3 Indicate if your activity was paid or volunteered.

Column 4 Indicate when your involvement with the organization ended. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each organization.

Organization	*Description and role*	*Paid or Unpaid?*	*End Date*	*For ASH Internal Use*

Other

3. Do you have other indirect interests in or relationships with any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

☒ No

☐ Yes

If yes, please explain:

Part C. Relevant Other Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

ASH Guideline Panel on Sickle Cell Disease-Related Stem Cell Transplantation

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

   ☒ No

   ☐ Yes

   If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

   ☒ No

   ☐ Yes

   If yes, what were those views and where were they made?

Non-Industry Supported Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part B, Question 1, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

☒ No

☐ Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

Funder	*Description of Research*	*My Role*	*End Date*

Institutional Relationships

4. Could your salary be affected by recommendations on this topic?

☐ Don't know

☒ No

☐ Yes

If yes, please explain:

5. Do you generate revenues for your institution or employer by clinical activity, teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

☐ Don't know

☒ No

☐ Yes

If yes, please explain:

6. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

   ☐ Don't know

   ☒ No

   ☐ Yes

   If yes, please explain:

Career Advancement

7. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

Involvement in Organizations With Relevant Policy Positions

8. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

   ☒ No

   ☐ Yes, as described below:

   Column 1 Name the organization.

   Column 2 Describe or reference any policy position of the organization that is related to the topic of these guidelines.

   Column 3 Describe your role at the organization, including your involvement in deciding, promoting, or implementing relevant positions.

   Add rows as needed for each organization.

Organization	*Relevant Policy Position*	*Your Role*

Clinical Practice

9. Do you see patients clinically?

☒ No

☐ Yes

If yes, what is your primary specialty or subspecialty?

If yes, do you prescribe or otherwise recommend clinical interventions (e.g., screening or diagnostic tests, evaluations, treatments, procedures) that may be addressed by these guidelines?

☒ No

☐ Yes

If yes, please explain:

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in this form?

☒ No

☐ Yes

If yes, please describe:

Part D. New Declarations (ASH Internal Use)

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
n/a	Unpaid intern for Sickle Cell Community Consortium (SCCC) from March 2018-October 2018.	1/14/19	Not a conflict. The Consortium is a nonprofit organization and Ms. Woolford held an unpaid, non-leadership role.
Bluebird Bio	Direct payment for participation in clinical round tables.	10/13/2020	Indirect conflict. Bluebird Bio is developing a gene editing platform for use in SCD patients. Although gene therapy will not be addressed in this guideline, the company could be indirectly affected by recommendations about transplantation because gene therapy is being developed as an alternative treatment to transplantation.
Novartis	Direct payment for speaking	10/13/2020	Indirect conflict. Novartis could be indirectly affected by this guideline: Novartis is developing a gene editing platform for treatment of SCD. Although gene therapy will be addressed in this guideline, the company could be indirectly affected by recommendations about transplantation because gene therapy

Company	*Description*	*Disclosure Date*	*ASH Internal Notes*
			is being developed as an alternative treatment to transplantation.
Agios	Direct payment for advisory board participation.	10/13/2020	Agios is not an affected company.

Part E. Summary (ASH Internal Use)

Name of guideline panel(s)	ASH Guideline Panel on Sickle Cell Disease-Related Stem Cell Transplantation

Summary of ASH Judgments About Financial Conflicts

Reviewer name and date	*Direct Financial Conflicts?*	*Indirect Financial Conflicts?*	*Management Notes*
Webb 3/6/17 Pai 3/13/17	No	No	
Webb 1/14/19	No	No	New disclosure. See Part D. above.
Alexander 11/1/2020	No	Yes	New disclosures. See Part D. On 10/13/2020, Ms. Woolford confirmed all information in this form.

Summary of Direct Financial Conflicts

Company	*Description*	*Disclosure Date*	*ASH Notes*

Other Notes

[Describe other disclosed interests or relationships that may be important to highlight to the guideline panel, guideline reviewers, and guideline users.]